Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
Study Identifier:
ALXN2070-19-515
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: andexanet alfa
Date
Jun 2021 - Nov 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 84 Years
Requirements Information
Sex
Female & Male
Age
18 - 84 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: andexanet alfa
Date
Jun 2021 - Nov 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 84 Years years
Requirements Information
Protocol Summary
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
Trial Locations
Location
Status
Location
Clinical Trial Site
Phoenix, Arizona, United States, 85006
Status
N/A
Location
Clinical Trial Site
Tucson, Arizona, United States, 85724
Status
N/A
Location
Clinical Trial Site
Long Beach, California, United States, 90806
Status
N/A
Location
Clinical Trial Site
Moreno Valley, California, United States, 92555
Status
N/A
Location
Clinical Trial Site
Washington, District of Columbia, United States, 20037
Status
N/A
Location
Clinical Trial Site
Sarasota, Florida, United States, 34239
Status
N/A